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Abstract
Background: Despite the considerable progress made in understanding the molecular bases of mitochondrial diseases, no
effective treatments have been developed to date. Faithful animal models would be extremely helpful for designing such
treatments. We showed previously that the Harlequin mouse phenotype was due to a specific mitochondrial complex I
deficiency resulting from the loss of the Apoptosis Inducing Factor (Aif) protein.
Methodology/Principal Findings: Here, we conducted a detailed evaluation of the Harlequin mouse phenotype, including
the biochemical abnormalities in various tissues. We observed highly variable disease expression considering both severity
and time course progression. In each tissue, abnormalities correlated with the residual amount of the respiratory chain
complex I 20 kDa subunit, rather than with residual Aif protein. Antioxidant enzyme activities were normal except in skeletal
muscle, where they were moderately elevated.
Conclusions/Significance: Thus, the Harlequin mouse phenotype appears to result from mitochondrial respiratory chain
complex I deficiency. Its features resemble those of human complex I deficiency syndromes. The Harlequin mouse holds
promise as a model for developing treatments for complex I deficiency syndromes.
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Introduction
Most of the energy produced in the cell comes from oxidative
phosphorylation (OXPHOS), which is catalyzed by the respiratory
chain (RC) embedded in the mitochondrial inner membrane [1].
The respiratory chain comprises the proton-pumping respirasome
[2] associating complexes I, III, and IV and a number of
dehydrogenases including complex II. Electrons from respiratory
substrates competitively converge from the various dehydrogenases
to the CIII-associated quinone pool and are then conveyed to
cytochrome oxidase and molecular oxygen by cytochrome c loosely
bound to the mitochondrial inner membrane. The pumped protons
are used to produce ATP from ADP and inorganic phosphate via
theenzymeATPase, whichassociates with adenylateand phosphate
carriers to form the ATP synthasome [3]. OXPHOS dysfunction
underlies a wide spectrum of human diseases, known as mitochon-
drial diseases. Respiratory chain complex I (RCCI) deficiency
contributes 30% to 40% of all cases of mitochondrial disease [4].
Features of RCCI deficiency include optic atrophy, cerebellar
ataxia, retinitis pigmentosa, growth retardation, and hypertrophic
cardiomyopathy [5]. The mechanism, tissue-specificity, and course
of mitochondrial diseases are poorly understood [6].
The number of reported human mitochondrial diseases has
increased considerably in recent years. The underlying mutations
affect either the mitochondrial DNA or the nuclear genes, of
which more than 100 have been incriminated [7]. Treatments are
extremely limited [8]. A major obstacle to the development of
effective treatments is the absence of reliable animal models.
Obtaining mice with mitochondrial DNA (mtDNA) mutations has
proved challenging, and the animals rarely transmit the mutant
mtDNA to their progeny, which limits their usefulness as tools for
designing treatments [9]. Targeting nuclear genes encoding
OXPHOS components has proved more efficient. However,
extinction of a majority of the nuclear OXPHOS genes caused
early embryonic death or produced no major phenotypic
abnormalities. Cre-Lox recombination, in contrast, has been
successful in producing mitochondrial abnormalities in specific
tissue types. Thus, studies of Tfam-KO and frataxin-KO mice
[10,11] have shed light on a number of pathological mechanisms.
However, the severe biochemical abnormalities in the target
tissues fail to replicate human mitochondrial disease, limiting the
value of these animal models for designing treatments. Recently,
targeting the NDUFS4 subunit of complex I produced mice that
exhibit several of the features seen in patients with RCCI [12].
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at 7 weeks of age, and the animals do not exhibit the extraordinary
variability in disease symptoms and course that characterizes
human RCCI deficiency.
We recently established the occurrence of partial complex I
deficiency in the Harlequin (Hq) mouse [13], which is character-
ized by progressive cerebellar ataxia [14]. Other features in these
animals include early fur abnormalities, optic tract dysfunction
with retinitis pigmentosa, and a risk of hypertrophic cardiomyop-
athy [14–16]. The Hq phenotype is due to a proviral insertion in
the X-linked gene encoding the mitochondrial protein Apoptosis
Inducing Factor (Aif) [14]. The insertion causes a partial decrease
in the Aif protein to about 20% of the amount seen in wild-type
mice. Gross development is not significantly affected, but the
animals exhibit the typical features of mitochondrial disease. Total
loss of Aif function caused abnormal cell death, presumably
related to RCCI deficiency, during embryonic development but
did not affect the temporal progression of patterning [17].
Although the involvement of Aif in RCCI assembly and stability
is still being investigated [18,19], the characteristics of the Hq
mouse make it a potential model to investigate complex I
deficiencies. With the aim to establish the value of this model,
our main objective was to study in details the course of the
abnormalities in Hq mice and the tissue-specific biochemical
features at various time points. We found that the temporal
progression of complex I deficiency differed across tissues and that
the involvement of each tissue correlated with the residual amount
of complex I 20 kDa subunit. Although oxidative injury has been
suggested as a key mechanism in the Hq phenotype [16],
antioxidant enzymes were normal except in skeletal muscle, where
they were moderately increased.
Results
I. The Harlequin phenotype course
The onset of most of the gross phenotypic abnormalities varied
widely across individuals. Although all the mutant animals
eventually developed the disease phenotype, the time-course
ranged from early ataxia and death to the slow development of
functional impairment over several months. These differences
were detected by monitoring body weight, fur abnormalities, and
ataxia.
Weight loss and growth retardation are common among
patients with RC disorders [20,21], we therefore first studied this
parameter in wild type and Hq mice. B6CBACa Aw-J/A-Pdcd8
mice are relatively small. Thus, in our study, the wild type mice
achieved their adult weight of 2762 g for males (n=19) and
2262 g for females (n=22) within 4 months. Body weight varied
widely in the hemizygous Hq/Y males (Fig. 1A) and homozygous
Hq/Hq females (Fig. 1C), with some Hq individuals having similar
weights to those of wild type animals. No growth retardation
occurred in the heterozygous females (Fig. 1B). At 1 month of age,
about half the Hq males had marked growth retardation with a
greater than 30% decrease in body weight compared to wild type
animals (Fig. 1D). Most of these animals had normal body weights
(within 30% of the control mean) at 3 months of age and
significantly decreased body weights at 6 months of age compared
to controls. However, 30% of Hq animals had no significant
growth retardation at 6 mo of age. Growth retardation probably
started before birth, as birth weight was significantly lower in the
Hq population than in the wild type population (1.260.2 g (n=15)
and 1.560.2 g (n=13) respectively; p,0.001). The sex ratio was
normal in all the litters and the number of Hq individuals was
consistent with Mendelian inheritance. About 30% of Hq animals
died during the 6-month study, with most deaths occurring
between 15 and 30 d of age. The only developmental abnormality
found in the Hq population was ocular hypoplasia with absence of
the optic nerve, which was noted in 40% of Hq individuals at 1 mo
of age. Ocular hypoplasia occurred at the severe end of the disease
spectrum and was present in many of the animals that died early
on. At 3 and 6 mo of age, ocular hypoplasia was present in 20%
and 10% of Hq animals, respectively. Ocular hypoplasia with
absence of the optic nerve has been previously reported in human
mitochondrial disease [22].
Paucity of fur was first described as the hallmark of Hq mice
[23]. We noted complete baldness in most of the Hq animals
initially (Fig. 2A) followed by some hair growth resulting in a
patchy or near-normal coat. At 3 mo of age, about half the Hq
animals were bald over more than 30% of their body surface area
and about 30% had near-normal fur. At 6 mo of age, 10% of Hq
animals had near-normal fur.
Ataxia was detected in most of the animals at 3 mo of age.
Severe ataxia defined as more than three falls within 5 minutes
was noted only late in the disease, at 6 mo of age (Fig. 2B). At
Figure 1. Time-course of weight loss in Harlequin mice. A: Weight
changes with age in Harlequin hemizygous males (Hq/Y; n=19) and
wild-type males (B6CBACa Aw-J/A-Pdcd8 strain; n=14). B, C: Weight
changes with age in wild-type (n=6) and heterozygous females (Hq/
Aif+; n=6) (B) and in homozygous females (Hq/Hq; n=6) (C). D: Weight
deficiency in Hq mice (n=25) compared to wild type mice (n=20) at
various ages. Dark squares and open circles indicate control and Hq
mice respectively.
doi:10.1371/journal.pone.0003208.g001
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severe ataxia. At 6 mo of age, 90% of Hq males and females had
marked gait ataxia but 8% had no clinical evidence of ataxia
(Fig. 2B; arrow).
We looked for correlations linking growth retardation, baldness,
and ataxia in the Hq population (Fig. 3, A–C). Plotting body
weight against percentage of surface area without fur at 6 mo of
age (Fig. 3A) showed that weight was highest in the animals that
had nearly complete coats and vice versa. The animals with higher
body weights were also those with less severe ataxia (Fig. 3B).
Ataxia was more severe in the animals with earlier disease onset
(Fig. 3C). Thus, body weight, baldness, ataxia, and age at onset
seemed to vary in lockstep.
Motor coordination used as a rough estimate of neurological
involvement was tested using a Rotarod device (Fig. 4). Perfor-
mance varied widely in the Hq and wild type animals at 3, 4, 5,
and 6 mo of age. A significant difference between Hq and wild
type animals was noticeable from 4 mo of age onward, with some
of the Hq animals performing very poorly at 4 mo of age.
II. Complex I defect and its consequences in Harlequin
mouse tissues
We previously reported partial loss of complex I activity by about
40% of the value in controls in the whole brain of Hq mice, with
variations in the severity of the deficiency across tissues and cells [13].
Here, we show that complex I activity was about 50% of the control
value in the cerebellum of Hq mice(Fig.5A).At6 moofage,complex
I deficiency was noted in all the brain territories investigated
(cerebellum, thalamus, and cortical-enriched fraction), as well as the
optic nerves (50% residual activity) and retinas (25% residual activity)
(Fig. 5A–D). Complex I deficiency was detected at 1 mo of age,
before the occurrence of cerebellar atrophy or major ataxia (Fig. 5), in
any of the 20 Hq animals at this time point. In other organs, complex
I activity was normal (heart, liver, and testis) or only slightly reduced
(by 20% in the spinal cord and 10% in the kidney).Complex I activity
was decreased by about 30% in the skeletal muscle (Fig. 5E). In most
oftheaffected tissues,complexIdeficiencyworsenedovertime,albeit
with a variable course (Fig. 5). The deficiency reached its greatest
level by 1 mo of age in the cerebellum and skeletal muscle. In the
thalamus, cortex, and optic nerve, in contrast, the deficiency was
modest or absent at 1 mo of age and reached 50% by 6 mo of age.
Complex I activity in the retinas was decreased by about 30% by
1 mo of age but improved subsequently, probably as a result of bias
due to gradual selection of animals with normal eyes.
Oxidative insult has been suggested as a key factor in the
pathogenesis of the Hq phenotype [16]. Superoxide dismutase
(SOD) and catalase activities are induced by oxidative insult in vivo.
We compared SOD and catalase activities at 6 mo of age in
control (n=10) and Hq (n=10) mice (Fig. 6A). Moderate delayed
Figure 2. Variability of baldness and ataxia severity in
Harlequin mice. A: Baldness in Hq mice. Open bars indicate severe
baldness (more than 70% of the body surface area) at ages when
controls had their full adult coat. Gray bars indicate patchy baldness
(less than 30% of the body surface area). Patch distribution varied
across animals. Dark bars represent animals with a full coat, many of
which had sparser hair than the controls. The arrow shows that a
substantial proportion of Hq mice had nearly normal hair at 3 and 6 mo
of age. B: Severe ataxia in Hq animals (open bars; three or more falls in
5 minutes) was detected only at 6 mo of age. The arrow shows that two
Hq animals had only mild ataxia at 6 mo of age.
doi:10.1371/journal.pone.0003208.g002
Figure 3. Correlations among the severities of the major abnormalities in Harlequin mice. A: Baldness (% body surface area) plotted
against body weight in Hq males (n=12). B, C: Ataxia (number of falls per min) plotted against body weight (B) or against the age at the first recorded
sign of ataxia (C).
doi:10.1371/journal.pone.0003208.g003
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of control values for SOD and catalase, respectively, at 6 mo of
age). However, the activities of these two enzymes were not
increased in any of the other tissues investigated in this study.
Since the extent of complex I deficiency varied across tissues, we
measured residual complex I using the 20 kDa subunit of complex
I as a marker. We reported previously that this subunit, now
recognized as NDUFB8 (see Material and Methods), was
decreased in case of Aif deficiency [24]. Western blot analysis of
skeletal muscle samples from Hq mice showed a 60% decrease
(Fig. 6B) in the 20 kDa subunit compared to controls, indicating a
30% decrease in complex I activity (Fig. 5E). Western blot analysis
was also performed with samples of heart, liver, kidney,
cerebellum, cortex, and spinal cord. We plotted the residual
complex I activities in these tissues, as measured previously,
against residual 20 kDa subunit (Fig. 6C). A significant correlation
was found between these two parameters. In particular, tissues
without complex I deficiency (e.g. heart, liver) contained normal
amounts of 20 kDa subunit.
We measured Aif content in various tissues of Hq mice and
controls (Fig. 7). In all studied tissues, one major (.98%) band at
57 kDa reacted with antibody to the Aif internal region. Heart
samples from control animals showed two bands, at 57 and about
30 kDa, in nearly identical proportions (Fig. 7A). In heart samples
from Hq animals, in contrast, the 57 kDa was extremely faint
(Fig. 7A–B). When we compared the residual amount of Aif
(57 kDa) in various tissues of Hq mice (n=6) and controls (n=3),
we found that Aif was barely detectable in the retinas and was
reduced to 20%–40% in most tissues except for the liver, where
the level was about 60% of the control value. We found no
correlation between the amount of residual Aif protein and tissue
involvement (Fig. 6D).
Discussion
The Hq phenotype is caused by severe Aif protein deficiency in
hemizygous males and homozygous females. Aif gene impairment
is due to an ecotropic proviral insertion in the first intron of the
Figure 4. Variable Rotarod performance in control and
Harlequin mice. Plots of individual results of three tests per animal
(3 mo: 16 wild-type and 13 Hq mice; 4 mo: 11 wild-type and 13 Hq
animals; and 5 and 6 mo: 15 wild-type and 11 Hq animals) showing the
wide variability of values in both the Hq and control populations at
each time point. The mean and standard deviation are shown for each
distribution. Despite the major variability, t-tests showed significantly
poorer performance in the Hq mice at 4 mo of age.
doi:10.1371/journal.pone.0003208.g004
Figure 5. Differences in the time-course and severity of complex I deficiency across tissues from Harlequin mice. A–F: Complex I activity
in homogenates prepared from cerebellum (A), thalamus (B), cortex (C), optic nerves (D), skeletal muscle (E), and retinas (F). Complex I activity was
measured by spectrophotometry [40] and normalized for the activity of complex V, which was not affected by Aif depletion. The open and dark
symbols refer to the control and Hq mice, respectively. Continuous lines indicate changes in complex I activity over time in various tissues of Hq mice.
The dotted line indicates changes in complex I activity over time in Hq retinas, presumably ascribed to biased sample collection. Numbers of animals
were as follows: 15 d of age, 3 controls and 3 Hq mice; 1 mo of age, 5 controls and 5 Hq mice; 3 mo of age, 5 controls and 5 Hq mice; 6 mo of age, 10
controls and 10 Hq mice. *p,0.005; **p,0.001.
doi:10.1371/journal.pone.0003208.g005
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deficiency in affected tissues of Hq mice [13], in ES cells [13] and
embryos [17] of Aif knock-out mice, in Aif knockdown human
HeLa cells [13], in mouse tissues (skeletal muscle, heart, liver) with
tissue-specific ablation of the Aif gene [24,25], and in Aif knockout
Drosophila [26]. These conditions are characterized by RCCI
deficiency without evidence of oxidative stress except in the
skeletal muscle, where SOD and catalase activities are increased
[24]. Evidence of antioxidant enzyme induction has led to the
suggestion that Aif may protect the mitochondria against oxidation
[16]. Primary complex I deficiency has been reported to result in
oxidative stress [27], but there is no evidence that oxidative stress
can specifically cause complex I deficiency. Impairment of
mitochondrial antioxidant enzymes (e.g., manganese-dependent
SOD) results instead in a generalized deficiency of the RC,
including the iron-sulfur cluster-containing enzymes (complexes I,
II, and III) and the Krebs cycle enzyme aconitase [28].
Accordingly, treatment of Aif-depleted human cells (Hep3B and
HeLa cell lines) with antioxidants (N-acetyl-cysteine or MitoQ)
failed to restore complex I integrity [29], suggesting primary loss of
complex I, which might increase superoxide leakage. Conversely,
the (pro-oxidant) superoxide-generating NADH oxidase activity of
Aif may be required for normal muscle regeneration [30]. Taken
in concert, the data suggest that any antioxidant effects of Aif may
be confined to the close vicinity of complex I, so that Aif acts as a
complex I maintenance protein. Antioxidant enzyme induction in
muscle-specific Aif knockout mutants [24] and in skeletal muscle
from our Hq mice appears to be tissue-specific and may reflect
either an additional role for Aif in muscle or a tissue-specific
consequence of RCCI. Although the role for Aif remains debated
[26,29,30], the effects of Aif deficiency are similar to those of
deficiency in any complex I assembly/maintenance factor.
NDUFS4 knockout mice exhibit severe RCCI with features
similar to those of Hq mice (growth retardation, blindness, ataxia,
and baldness) but greater disease severity leading to death at 7
weeks of age after only 2 weeks with symptoms. Thus, complex I
Figure 6. Antioxidant enzymes and Complex I 20 kDa subunit in various tissues of Harlequin mice. A: Superoxide dismutase
(manganese- and copper, zinc-dependent SODs) activity and catalase activity measured as described in Materials and Methods in skeletal muscle
tissue from Hq mice at various ages. B: Western blot analysis of Aif, complex I 20 and 39 kDa subunits (ND6 and NDUFA9, respectively) and porin in
skeletal muscle of Hq mice (lines 1, 2) and control mice (3, 4). C: Plot of residual complex I 20 kDa subunit in mouse tissues against residual complex I
activity, showing a significant correlation. D: Plot of residual Aif in mouse tissues against residual complex I activity, indicating no significant
correlation.
doi:10.1371/journal.pone.0003208.g006
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NDUFS4 knockout models.
Multivisceral disease develops in Hq mice over time. As with
human complex I-associated diseases, the brain and optic tract are
affected [5], whereas the liver is spared. We failed so far to obtain a
clear analogy between the standard Leigh syndrome images
observed in a number of patients with complex I deficiency and
the Hq mice. Similarly, T2-weighted MRI images showing signal
hyper intensity have not been reported for the NDUFS4 mutant
mice. Disease progression follows the same pattern in all NDUFS4
knockout mice but varies considerably across Hq mice. As with
humans, both genetic and non-genetic factors may explain this
variability, since the animals do not have a pure genetic
background (B6CBACa Aw-J/A-Pdcd8) and the phenotypic
consequences of mitochondrial dysfunction depend on a number
of unidentified factors. Marked inter-individual variability also
occurs in human mitochondrial diseases. Thus, the Hq model,
although difficult to study, constitutes a good model of human
mitochondrial diseases. Obviously, as long as the intimate
mechanism linking Aif depletion and impaired complex I
deficiency is not fully depicted, this model will be best used to
test for efficiency of compounds/strategies aiming at counterbal-
ancing the consequences of complex I deficiency.
Reduced birth weight was the earliest abnormality in Hq
animals compared to their wild type littermates and suggested
intra-uterine growth retardation (IUGR). Similarly, Aif-KO mouse
embryos had severe growth retardation contrasting with a normal
temporal progression of patterning [31]. Among humans with
RCCI deficiency, 23% had low birth weights [20]. In mice,
complete Aif gene deletion not only caused early deaths by
embryonic day E9 related to RCCI deficiency [32], but also
resulted in marked embryonic growth retardation [17]. Body
weight in our Hq animals was low at birth and subsequently
remained lower than in the control animals. The mechanism of
IUGR associated with RC deficiencies remains unclear. In
humans, early antenatal expression of respiratory chain deficien-
cies (including RCCI deficiency) reflects the time-course of disease-
causing-gene expression in utero [20]. In utero, respiratory chain
deficiency may result in decreased ATP formation and/or in
alteration of apoptotic events controlled by the mitochondria.
Hair abnormalities occur in a substantial proportion of human
patients with mitochondrial disorders. In 8 of 25 children with
mitochondrial diseases, slow-growing, sparse, fragile hair was an
early manifestation [33]. This fact, together with the hair
abnormalities seen in NDUFS4 knockout mice, supports a role
for RCCI deficiency in the hair abnormalities of Hq mice. The
correlation in our Hq mice between the severity of baldness and
the severity of growth retardation also suggests a role for RCCI
deficiency in the hair abnormalities, as delayed growth is probably
due to RCCI deficiency.
The severity of cerebellar ataxia varied widely in our Hq mice,
probably reflecting a variable degree of neuron loss. Similar
variability occurs in humans with mitochondrial disorders [6]. The
greater severity of ataxia at 6 mo of age in a subset of our Hq
animals compared to an earlier study [14] suggests a role for
unidentified environmental factors and a possible influence of the
mixed genetic background. Interestingly, complex I deficiency in
the cerebellum was readily evidenced at 15 d of age, whereas
cerebellar ataxia was detected only after several weeks in the most
severely affected animals. Thus, cerebellar function persisted for
several weeks despite the presence of complex I-deficient
mitochondria.
Our study does not shed new light on the mechanism of the
tissue specificity associated with complex I deficiency. However,
our data establish that residual complex I measured using the 20-
kDa subunit as a marker correlates with the residual complex I
activity in affected tissues. In contrast, residual complex I activity
was not correlated with residual Aif protein. Five Aif isoforms have
been identified to date [34], suggesting a possible explanation for
the variability of tissue involvement. In control hearts, a shorter
isoform contributes as much as 50% of total Aif. The normal
complex I activity in the heart may be ascribable to the presence of
this short Aif isoform, whose electrophoretic properties resemble
those of the Aif-sh 2 [34].
Taken together, our results indicate that Hq mice replicate the
main features of RCCI deficiency in humans, including tissue-
specificity, course, and interindividual variability. The Hq model is
likely to prove valuable for investigating treatments aimed at
RCCI deficiency.
Materials and Methods
Animals
Homozygous (Hq/Hq) females and hemizygous (Hq/Y) males
were obtained by mating Hq/X females with either Hq/Y or
control males obtained from The Jackson Laboratory (Bar
Harbor, ME). The Hq strain was B6CBACaA
w-J/A-Pdc8
Hq/J.
Figure 7. Aif in Harlequin mice. A: Western blot analysis of Aif in the
heart of Hq mice (lines 1–6) and control mice (lines 7–9). In the heart,
two bands reacted with the Aif antibody. The band with the highest
molecular weight was produced by the Aif1 isoform (molecular weights
of the unprocessed and processed forms, 67 and 57 kDa, respectively).
The molecular weight of the other band is consistent with the Aif sh2
isoform. This second form was not detected in any of the other tissues
studied (cerebellum, spinal cord, cortex, retinas, skeletal muscle, kidney,
or liver). Porin was used as a loading marker. B: Proportion of the two
Aif isoforms identified in the heart of control mice (open symbol) and
Hq mice (dark symbol) mice. C: Aif (57 kDa) content in various tissues of
control and Hq mice normalized for porin content. **p,0.005;
***p,0.001.
doi:10.1371/journal.pone.0003208.g007
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having a mixed genetic background. The mice were housed with a
12-h light/dark cycle and free access to food (3% lipids, 16%
protein; SAFE A-04 chow; UAR Epinay sur Orge, France) and
water.
Genotype determination
Mice were genotyped using multiplex PCR with five primers:
two for sex determination (SRY: 59-TGGGACTGGTGA-
CAATTGTC-39 and 59-GAGTACAGGTGTGCAGCTCT-39),
two for the wild-type Aif allele (Aif 1F: 59AGTGTCCAGT-
CAAAGTACCGG-39; Aif 1R: 59-CTATGCCCTTCTCCATG-
TAGTT-39), and one for the Aif allele harboring the proviral
insertion (Hq allele) (Aif RV: 59-CCCGTGTATCCAA-
TAAAGCCTT-39).
Phenotype determination
Three hallmarks of the Hq phenotype [14] were studied:
baldness, growth retardation, and cerebellar ataxia. Baldness was
assessed as the percentage of body surface area without hair.
Weight was determined daily from birth through day 7 of
postnatal life and weekly thereafter. Cerebellar ataxia was assessed
as the number of falls per minute of walking, with severe ataxia
being defined as three or more falls within 5 minutes; and by
testing on a computer-driven Rotarod device (Imetronic; Pessac,
France). The mice were trained at 3, 4, 5, and 6 mo of age, for 3
consecutive days after a previous day of training, at speeds that
increased from 4 to 40 rpm/min.
Tissue homogenate preparation and enzyme assays
Frozen tissue (cortex, cerebellum, thalamus, spinal cord, optic
nerve, retinas, heart, liver, kidney, skeletal muscle, testis)
homogenates were prepared using a 1 ml glass-glass potter in
500 ml of extraction buffer composed of 0.25 mM sucrose, 40 mM
KCl, 2 mM EGTA, 1 mg/ml BSA, and 20 mM Tris-HCl
(pH 7.2). Large cellular debris was separated by centrifugation
(1500 g65 min). RCCI activity was measured as recently
described using a Cary 50 spectrophotometer (Varian Australia,
Victoria, Australia) [35]. Catalase activity and total SOD level
were quantified as already described [36,37]. Protein was
estimated using the Bradford assay [38].
Western blot analysis
Western blot analysis was performed on mitochondria-enriched
supernatant (900 g65 min) prepared from tissue homogenate
separated by SDS-PAGE, and blotted onto a PVDF membrane.
The membranes were blocked for 1 h in TBST tween 0.01% and
then incubated for 1–3 h with different antibodies (AIF1:1000,
chemicon; complex I subunits 20 kDa and 39 kDa:1:1000,
Molecular Probes and porin 1:1000, MitoSciences. It must be
mentioned that future controversy about the identity of the
20 kDa antibody may occur, because different lines of evidence
suggest that, in fact, the protein recognized by the antibody
provided by Molecular Probes is not ND6, but a different complex
I membrane arm subunit, NDUFB8, with a similar molecular
weight as ND6 (Dr Jose Antonio Enriquez, University of
Zaragoza, Spain, personal communication to Dr Fernandez-
Moreira) [39]. The horseradish peroxidase-conjugated secondary
antibody (1:5000) was incubated for 1 h at room temperature in
5% milk powder in TBST buffer, 0.01% Tween 20. Peroxidase
activity was visualized with the ECL plus (GE healcare) according
to the manufacturer’s instructions. Chemiluminescent signal were
captured on autoradiography and used to assess protein content.
The relative protein levels of AIF and Complex I 20 kDa subunit
were assessed by their chemiluminescent signals compared with
that of the porin protein.
Statistics
We evaluated mean differences in study variables between Hq
and wild-type populations by using appropriate t-tests (SigmaStat
software, Richmond, CA) to compute the means, standard
deviations, and p values as indicated. Values of p less than 0.001
were considered statistically significant.
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